IN-ARMOR optimises nanocarriers for targeted delivery of host-directed therapies
Sep 25, 2026. The [...]
IN-ARMOR completes an important step in the safety assessment of its therapeutic candidates
Sep 25, 2026. The [...]
IN-ARMOR advances the characterisation of its lead compounds for host-directed therapies
Sep 23, 2026. The [...]
IN-ARMOR Consortium Meets in Madrid to Consolidate Scientific Progress and Shape the Roadmap Towards the Final Phase
Sep 18, 2026. On [...]
IN-ARMOR completes its 2nd Periodic Review
Jul 8, 2026. The [...]
Biokeralty Presents the Use of Artificial Intelligence in the IN-ARMOR Project at the TUAI European Consortium’s Spring School
Jul 6, 2026. Earlier [...]
IN-ARMOR Featured by Basque Innovation Agency SPRI
Jun 16, 2026. The [...]
IN-ARMOR Consortium Holds 13th Management Board Meeting to Strategize for Upcoming Project Review and Clinical Transitions
Jun 1, 2026. On [...]
The IN-ARMOR project gains visibility in the Icelandic press with its innovative approach to tackling antimicrobial resistance
12 May, 2026. [...]
New IN-ARMOR publication in the Journal of Medical
24 Mar, 2026. [...]